Compare KB Financial Group, Inc. (KB) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KB Financial Group, Inc. vs Medtronic PLC — how do they compare? KB Financial Group, Inc. trades at $122 (market cap $42.62B), while Medtronic PLC trades at $89.19 (market cap $112.24B). The key difference: Medtronic PLC is far larger — about 2.6× KB Financial Group, Inc.'s market cap, and Medtronic PLC pays the higher dividend (3.28%). Which is the better fit depends on your goals — on Pluang, investors hold KB Financial Group, Inc. for 33 Days and Medtronic PLC for 63 Days on average.
| KB | MDT | |
|---|---|---|
Market Cap | $42.62B | $112.24B |
Volume | 164,291 | 105,663,236 |
Sector | Financials | Health |
52-Week High | $132.88 | $105.35 |
52-Week Low | $77.50 | $73.75 |
Typical Hold Time | 33 Days | 63 Days |
Enterprise Value | $215.53T | $131.58B |
Dividend Yield | 2.71% | 3.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KB Financial Group (KB) trades at $124.73, showing minimal daily movement with a slight decline of 0.02%. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and improving profitability metrics. Technical indicators suggest a neutral near-term outlook, while analyst sentiment leans cautious with a 66.7% hold rating. Recent news highlights institutional interest and positive momentum coverage from financial media.
The outlook for KB appears balanced with attractive valuation metrics including a P/E of 9.68 and P/B of 0.94 suggesting potential undervaluation. However, the mixed analyst consensus and elevated EV/EBITDA of 21.71 warrant caution. Key risks include exposure to South Korean economic conditions and banking sector volatility, while opportunities lie in continued earnings growth and dividend potential.
Medtronic (MDT) trades at $85.51, down 1.81% on the day, with the stock showing bearish technical signals despite strong fundamental performance. The company has beaten earnings expectations for three consecutive quarters, maintains a healthy 13.93% net income margin, and offers a solid 3.2% dividend yield with 49 consecutive years of dividend growth. Recent positive developments include FDA clearances for new medical technologies and raised full-year guidance.
MDT presents a compelling value opportunity with analyst consensus pointing to 14% upside to the $97.80 price target. The stock's current valuation multiples (P/E 21.61, P/S 3.01) appear reasonable given the company's stable revenue growth and strong cash flow generation. Key risks include increasing debt levels and competitive pressures in the medical device sector, but the company's dividend aristocrat status and improving operational performance support a positive long-term outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
